文献

文献2018-11-13T02:58:39+00:00
Wedding Rigorous Scientific Methodology and Ancient Herbal Wisdom to Benefit Cancer Patients: The Development of PHY906
Oncology, February, 2018
Pilot trial of KD018 with neo-adjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer
ASCO, June 2017
PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment
Scientific Reports, March 2015
The Art and Science of Traditional Medicine – Part 2: Multidisciplinary Approaches for Studying Traditional Medicine
Science, January, 2015, article S43
The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018)
BMC Complementary and Alternative Medicine, July 2014
First-in-human Phase II trial of the Botanical Formulation PHY906 with Capecitabine as Second-line Therapy in Patients with Advanced Pancreatic Cancer
Cancer Chemotherapy Pharmacology, December 2013
Preclinical Studies of the Chinese Herbal Medicine formulation PHY906 as a Potential Adjunct to Radiation Therapy
International Journal of Radiation Biology, January 2013
Old formula, new Rx: The journey of PHY906 as cancer adjuvant therapy
Journal of Ethnopharmacology, April 2012
A Phase I Study of the Chinese Herbal Medicine PHY906 as a Modulator of Irinotecan-based Chemotherapy in Patients with Advanced Colorectal Cancer
Clinical Colorectal Cancer, June 2011
Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment
BMC Medical Genomics, May 2011
The Four-Herb Chinese Medicine PHY906 Reduces Chemotherapy-Induced Gastrointestinal Toxicity
Science Translational Medicine, August 2010
Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies
Phytomedicine, March 2010
Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma
Anticancer Research, October 2009
A phase II study of capecitabine (CAP) plus PHY906 in patients (pts) with advanced pancreatic cancer (APC)
Journal of Clinical Oncology, 2009
Chinese Herbal Formulation PHY906
National Cancer Institute Drug Dictionary